Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. [electronic resource]
Producer: 20161103Description: 858-67 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- pharmacokinetics
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacokinetics
- Biomarkers, Tumor -- blood
- Chemokine CCL2 -- blood
- Colorectal Neoplasms -- blood
- Cytokine TWEAK
- Female
- Gene Expression
- Humans
- Male
- Matrix Metalloproteinase 9 -- blood
- Maximum Tolerated Dose
- Middle Aged
- Receptors, Tumor Necrosis Factor -- blood
- TNF Receptor-Associated Factor 1 -- metabolism
- TWEAK Receptor
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.